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Abstract
Background: Many primary care patients with raised blood pressure or depression drink potentially hazardous
levels of alcohol. Brief interventions (BI) to reduce alcohol consumption may improve comorbid conditions and
reduce the risk of future alcohol problems. However, research has not established their effectiveness in this patient
population. This study aimed to establish the feasibility of definitive trials of BI to reduce excessive drinking in
primary care patients with hypertension or mild to moderate depression.
Methods: Thirteen general practices in North East England were randomized to the intervention or control arm of one
of two parallel pilot trials. Adult patients drinking excessively and diagnosed with hypertension or mild-to-moderate
depression received the Alcohol Use Disorders Identification Test (AUDIT) by postal survey. Consenting respondents
scoring more than 7 on AUDIT (score range 0 to 40) received brief alcohol consumption advice plus an information
leaflet (intervention) or an information leaflet alone (control) with follow-up at six months. Measurements included the
numbers of patients eligible, recruited, and retained, and the AUDIT score and systolic/diastolic blood pressure of each
patient or the nine-item Patient Health Questionnaire (PHQ-9) score. Acceptability was assessed via practitioner
feedback and patient willingness to be screened, recruited, and retained at follow-up.
Results: In the hypertension trial, 1709 of 33,813 adult patients (5.1%) were eligible and were surveyed. Among
the eligible patients, 468 (27.4%) returned questionnaires; 166 (9.6% of those surveyed) screened positively on
AUDIT and 83 (4.8% of those surveyed) were recruited (50.0% of positive screens). Sixty-seven cases (80.7% of recruited
patients) completed follow-up at six months. In the depression trial, 1,044 of 73,146 adult patients (1.4%) were eligible
and surveyed. Among these eligible patients, 215 (20.6%) responded; 104 (10.0% of those surveyed) screened positively
on AUDIT and 29 (2.8% of those surveyed) were recruited (27.9% of positive screens). Nineteen cases (65.5% of recruited
patients) completed follow-up at six months.
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Conclusions: Recruitment and retention rates were higher in the hypertension trial than in the depression trial. A full
brief intervention trial appears feasible for primary care patients with hypertension who drink excessively. High AUDIT
scores in the depression trial suggest the importance of alcohol intervention in this group. However, future work may
require alternative screening and measurement procedures.
Trial registration: Current Controlled Trials ISRCTN89156543; registered 21 October 2013.
Keywords: Alcohol, Screening, Brief intervention, Comorbid, Hypertension, Depression, Primary care, Trial, Preventive,
Feasibility
Background
Excessive alcohol consumption is currently the second
greatest risk to public health in developed countries [1]
and it affects a wide range of physical and mental health
problems [2,3], including hypertension and depression.
Hypertension is the leading risk factor for global disease
burden [4] with 50% prevalence in those aged over
50 years in the United Kingdom [5]. Depression con-
tributes 12% of the total burden of non-fatal global dis-
ease and is likely to be ranked as the world’s second
most disabling disease after cardiovascular disease by
2020 [6]. In the United Kingdom, mixed anxiety and
depression is prevalent in 11% of individuals aged be-
tween 16 and 74 years [7]. Alcohol consumption also
has one of the strongest associations with adverse
blood pressure changes [8-13] and excessive drinking
is a risk factor for developing hypertension [14], strokes
[15], and cardiovascular disease [11,16,17], while the
association between depression and alcohol use is well-
established, with high rates of co-occurrence recog-
nized [11,18-20].
Addressing the co-occurrence of excessive drinking and
these comorbid conditions should be a key priority for
public health. A recent five-year cohort study provided
support for excessive drinking as a cause of depressive
symptoms [21] and reductions in alcohol consumption
can lead to reductions in blood pressure [8,10,12,22-24].
Comorbidity may lead to worse alcohol-related outcomes
than an alcohol use disorder alone [19,25]; however,
comorbid populations may be particularly responsive
to interventions to reduce their drinking [26,27]. Pri-
mary care has considerable potential as a setting for
such interventions. Excessive drinkers make up 20% of
patients presenting to primary care, and hypertension
and depression are two of their most common comor-
bid conditions; patients with chronic conditions are
also regular and frequent users of primary care [28]. A
2007 audit in 34 primary care practices in one United
Kingdom regional authority found that of 30,911 patients
on a hypertension register and 28,697 patients on a depres-
sion register, 26% were excessive drinkers [29]. Until recently,
most practitioners under-recognized the role of excessive
drinking in the chronic conditions that they treated [30].
Screening to facilitate case recognition with brief alco-
hol intervention, consisting of structured advice and/or
behaviour change counselling (SBI), is a strategy that
can reduce excessive drinking in primary care patients
by approximately seven drinks each week [31]. Such a
reduction in alcohol consumption could have an impact
on comorbid physical or mental health problems. How-
ever, most previous trials of brief intervention to reduce
excessive drinking have excluded patients diagnosed
with specific comorbidities and have not measured the
impact of reduced drinking on those conditions [32]. A
recent systematic review [33] identified only 11 brief
intervention trials where participants had a recognized
substance use problem (alcohol, tobacco, or other drug
use) as well as a comorbid physical condition (3 trials)
or mental health problems (8 trials). This review found
positive outcomes of brief intervention in three trials
where substance-using patients had a comorbidity of
hypertension [26,34] or another physical condition
[35]; both of the former trials were based in primary
care. The impact of brief intervention in substance-
using patients with comorbid mental health problems
was equivocal, with both positive and null effects [33].
The two trials that focused on alcohol use reported
positive drinking outcomes in hospital patients with
schizophrenia and a range of psychiatric conditions
[36,37]. However, these two studies included patients
with relatively severe mental health problems and
found no changes in mental health states. The findings
of this review suggest that the evidence from relevant
trials in this field is insufficient to draw firm conclu-
sions about the impact of brief alcohol intervention on
linked health conditions, particularly in a primary care
context.
If feasible, a trial of SBI for alcohol in patients with
comorbid health conditions that measured changes in
health state as well as in drinking would address this
gap in knowledge. In line with recommendations for
the development of complex interventions [38] the current
pilot trials aimed to establish whether a definitive random-
ized controlled trial of brief alcohol intervention in patients
drinking excessively with a comorbidity of hypertension or
depression would be feasible in the United Kingdom.
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Specifically, the objectives of this study were to establish:
rates of eligibility, recruitment, and retention in the pilot
trials in the two patient populations (as the feasibility ob-
jective, these rates were the primary focus for the pilot);
numbers of primary care patients identifiable with hyper-
tension or mild/moderate depression who were excessive
drinkers (scoring 8 or above on the AUDIT tool) [39]; ac-
ceptability to patients and practitioners of intervention and
research materials and procedures; practicality of outcome
measures of health variables (alcohol use disorder risk,
blood pressure, and depression) that were proposed for a
full trial, operationalized as the number of patients in
which these measures were achieved.
This article reports the design and results of these par-
allel trials, along with a discussion of these in relation to
published literature and considers whether full trials are
supported by this feasibility work.
Methods
Design
Two parallel two-arm cluster randomized controlled
pilot trials were carried out. On advice from our trial
steering group, we focused on only one comorbid condi-
tion per practice to reduce the burden of research work
on staff. General practices were each randomly allocated
to one trial using computer-generated random numbers
(defined by comorbidity conditions of either hypertension
or mild to moderate depression) and then one arm of that
trial (either brief intervention (structured brief advice) or
control (information leaflet)). Cluster randomization was
chosen to match the likely design in a definitive trial to
prevent contamination from GPs trained to deliver brief
alcohol advice using these skills with control patients.
Randomization to trials was undertaken to avoid giving
practices the opportunity to select a trial corresponding to
a preferred condition, which might introduce bias. Pa-
tients were not informed which arm of the trial their prac-
tice had been allocated to [40].
Setting
Eighty-two general practices in the North East of
England were invited to take part in the study in two
waves. In the first wave, 27 general practices with prior
involvement in research (‘research practices’) from three
primary care trusts (PCTs) were approached, as well as all
remaining practices (n = 24) with a patient list over 4,000
in one of those PCTs. Fourteen of the research practices
were approached by an appointed research facilitator
working for one PCT and the remainder received an email
invitation from the university-based research team ad-
dressed to either the practice managers or one of the GP
partners, with telephone follow-ups on the practice man-
agers after two weeks. In a second wave of recruitment
eight months later, the research team re-invited eight
practices that had been too busy at the first wave (one a
research practice) plus five practices with prior involve-
ment in research from three neighboring PCTs, and 26
further practices with a patient list over 9,000 from across
all six PCTs.
Prior to randomization, all practices who agreed to
participate were asked to complete a series of anonym-
ous searches of their databases, respectively for male
and female patients aged 18 or above who had a coded
record of: drinking excessively (weekly alcohol consump-
tion recorded as more than 21 units per week for men
or more than 14 units per week for women, or scoring
positively on a validated screening tool for alcohol con-
sumption such as AUDIT, FAST, or SASQ); a diagnosis
of hypertension; depression or low mood but no referral
to specialist services for this; both excessive drinking
and a diagnosis of hypertension; both excessive drinking
and depression (or low mood).
The database search strategy is provided in detail in
Additional file 1. No date limit was set on the searches,
apart from those conducted at the last five practices re-
cruited. As screening and recruitment proceeded it had
become apparent that many patients were excluded at
baseline appointments due to their symptoms having
improved since their record of depression on the data-
base. To reduce the burden upon patients of attending
an appointment only to be excluded from the study, the
depression codes in searches for eligible patients at the
last five practices were therefore limited to the preceding
year. Those drinking excessively and having a recorded
diagnosis of hypertension, or drinking excessively and
having mild to moderate depression, were deemed to
meet initial eligibility criteria (referred to henceforth as
‘database eligible’).
The eight practices (median adult patient list size
7917, range 5562 to 13611) that had identified the lar-
gest numbers of comorbid patients were approached to
participate in the two pilot trials; they included four re-
search practices. These practices were randomized equally
to the two arms in each of the two parallel trials, that is,
two practices in each of the depression control (DC), de-
pression intervention (DI), hypertension control (HC),
and hypertension intervention (HI) categories. Before
questionnaires were sent out to patients one practice
(allocated to DI) withdrew because there was no fund-
ing to support their involvement and another (allocated
to HI) withdrew because of GPs’ subsequent concerns that
patients might not wish to be asked about their alcohol
consumption. One of these practices agreed that the re-
sults of their database searches could still be included to
establish prevalence, the other practice did not respond
when this was queried. A ninth research practice that had
also identified a large number of comorbid patients was
approached, replacing the practice which had dropped out
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of the depression trial (the first to withdraw). At the sec-
ond wave, a recruitment target of 30 patients per arm had
already been exceeded in the hypertension trial; practices
approached were therefore invited to participate in the de-
pression trial only. Six practices (median adult patient list
size 4848, range 4694 to 10464), including one research
practice, agreed and were randomized in equal numbers
to either DI or DC. The final number of practices per trial
arm was therefore two practices in HC, one practice in
HI, five practices in DC, and five practices in DI.
Participants
Patients meeting initial eligibility criteria but confirmed
by GPs as having a severe mental health disorder, cogni-
tive impairment, or terminal illness, or accessing treat-
ment for alcohol use, were excluded from further
consideration. All remaining ‘database eligible’ patients
were sent a trial pack containing a letter on practice-
headed paper with a GP’s signature inviting them to
participate by returning a questionnaire, a patient in-
formation leaflet relevant to the trial to which their
practice was allocated, a screening questionnaire com-
prising the 10 items of the Alcohol Use Disorder Identifica-
tion Tool (AUDIT) tool [39] and requesting demographic
and contact details for patients who wished to be consid-
ered for the trial, and a reply-paid envelope addressed to
Newcastle University for questionnaire return. No subse-
quent reminders were sent.
Patients who returned a questionnaire with a score of
8 or more on the AUDIT and who volunteered their
contact details were deemed ‘screen eligible’. A member
of the research team contacted these participants dir-
ectly by telephone to arrange an appointment with a re-
searcher at the patient’s surgery (the premises at which
they were registered with their GP practice); appoint-
ments were not offered in any other location. If the
participant did not attend the appointment a further
appointment was negotiated with the patient at a con-
venient time. Patients were offered a maximum of three
separate appointments. Up to seven attempts were made
to contact an eligible respondent by phone. If it had not
been possible to arrange an appointment after seven
phone calls at different times of day (including weekends
and evenings) a final letter was sent offering an appoint-
ment at a given time; no further appointments were of-
fered if the participant did not attend on this occasion. If
at any point a respondent indicated a wish to withdraw
from the study, they were thanked for their interest and
not contacted any further. Any data collected on the pa-
tient to that point was retained and participants were not
asked their reasons for withdrawing if they chose to do so,
in keeping with the terms of the consent agreement.
At the appointment, the trial was explained in more
depth and any queries discussed, following which the
patient was invited to give written consent to participate.
A baseline measurement of participants’ comorbid con-
dition was taken as described under ‘Measures’ below. If
the participant was still eligible at this stage (‘fully eli-
gible’), the intervention was delivered by the researcher
according to allocation status. Recruitment commenced
on 31 January 2011, with the final follow-up interview
carried out on 28 February 2012.
Interventions
At all baseline interviews patients received either an ad-
vice leaflet produced by the British Heart Foundation
(hypertension trial) or a leaflet on depression produced
by a regional NHS organization (depression trial). In
control practices this was the only deviation from usual
care following baseline assessment.
At practices randomized to the intervention arms only,
university research staff (GW and CW) delivered five
minutes of structured advice on alcohol consumption at
baseline, tailored to the patient’s physical or mental health
comorbidity. The brief advice (see Additional file 2) con-
sisted of personalized, structured feedback to patients
about their level of alcohol-related risk or harm, a visual
normative comparison of where their drinking behaviour
sat in relation to population norms, health benefits associ-
ated with reducing alcohol consumption from their
current levels, and practical suggestions on how to re-
duce drinking levels.
Materials were designed for the study and based on
those used in previous research on brief interventions
(BI) in primary care [41]. Research staff received training
in intervention delivery from an experienced alcohol
interventionist (RM) who also observed the initial four
interventions in the depression trial in order to assess fi-
delity. On these occasions the observer’s presence and
the voluntary nature of observation was explained be-
forehand and patients were invited to ask any questions
and give verbal consent before observing.
Outcomes
Primary outcome for a main study
It was envisaged that the primary outcome in a main
study following either trial would be risk of alcohol use
disorders. This was to be assessed using AUDIT, which
is considered the ‘gold standard’ screening tool for iden-
tifying excessive drinking and is brief, reliable, and valid
for use in primary care settings [39]. Ten items are each
rated from 0 to 4 (full score range 0 to 40); total scores
of 8 to 15 (inclusive) identify hazardous alcohol use
whilst total scores of 16 to 19 (inclusive) identify harm-
ful alcohol use, and a score of more than or equal to 20
indicates probable dependence [3]. A cutoff score of 8
was adopted in both trials, at which point AUDIT has a
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sensitivity of 92% and a specificity of 94% for risk drink-
ing in adults [39].
Secondary outcomes for a main study
The secondary outcomes envisaged for a main trial based
on the hypertension trial were systolic and diastolic blood
pressure. These were measured in the pilot hypertension
trial by a researcher taking single, seated readings of sys-
tolic and diastolic blood pressure in the patient’s surgery
at baseline and follow-up. A commercially available blood
pressure monitor with arm cuff (Kinetik Medical Devices
Ltd., Elstree, United Kingdom; endorsed by the British
Hypertension Society) was used in accordance with the
manufacturer’s instructions. At baseline this constituted
measurement of outcome rather than a clinical assess-
ment; no eligibility criterion was applied at this stage of
the hypertension trial.
The secondary outcome envisaged for a main trial
based on the depression trial was severity of depression,
measured at baseline and six-month follow-up using the
nine-item Patient Health Questionnaire (PHQ-9). This is
a brief, reliable, and valid screening tool that has been
extensively used for clinical and research purposes with
primary care patients [42,43] and is a responsive meas-
ure of outcome in depression treatment [44]. Nine items
are each rated from 0 to 3 (full score range 0 to 27). The
PHQ-9 has demonstrated an 88% sensitivity and an 88%
specificity for detecting mood disorders in adult primary
care patients using a cutoff score of 10 or more [45].
Consenting patients in the depression trial were in-
cluded as eligible at the baseline appointment if they
scored 5 to 19 inclusive, which indicates mild as well as
moderate and moderately severe depression [45,46]. Pa-
tients scoring outside this range were excluded: a score
below 5 indicated a healthy range, and a score over 19
indicated a patient suffering severe mental health prob-
lems, for whom research participation might represent
an unacceptable burden.
Pilot studies are a valuable means to assess practicality
of primary and secondary outcome measures for a main
trial [47]. For this purpose, descriptive statistics were
calculated for all the measures described above (AUDIT,
systolic and diastolic blood pressure, and PHQ-9 scores).
Feasibility outcomes
Feasibility was based on a combination of acceptability and
efficiency measures. An acceptable identification strategy
was defined as the ability to successfully identify from pa-
tient notes (database eligible) a pool of hazardous or harm-
ful drinkers with a comorbidity of hypertension or mild to
moderate depression who were willing to be screened on
these parameters in their general practice. Efficient recruit-
ment and retention was defined as the ability to recruit eli-
gible (screen positive) patients into the intervention stage
of the study and retain them at six-month follow-up. The
measures of these feasibility outcomes were the rates for
each pilot trial of patient eligibility; recruitment; and reten-
tion at six-month follow-up.
Follow-up
Six months after the baseline appointment, all partici-
pants were contacted by a researcher via telephone and
asked to participate in a follow-up appointment at which
outcome measurements were repeated (AUDIT and PHQ-
9 score or blood pressure reading). This was arranged at a
convenient time for them at their GP practice. If it did
not prove possible to contact a participant by phone, a
letter was sent from the research team inviting them to
an appointment at their GP surgery at a fixed time.
Any views expressed by patients at these appointments
were noted.
Sample size
A sample size calculation was not carried out to deter-
mine the number of clusters or patients for either of
these trials; sample size calculations are not a prerequis-
ite for pilot studies [48] and general recommendations
are not available to determine numbers of clusters if ran-
domizing by cluster in these studies [49]. Following rec-
ommendations for pilot trials randomizing by individual
patients (also cited for trials randomizing by cluster)
[40,49], a target figure of 30 patients recruited per arm
was sought at baseline (120 patients overall).
Feasibility criteria
Acceptability of identification strategy Previous screen-
ing in primary care has found that 35% of adult patients
are likely to be hazardous or harmful drinkers [50].
However, such studies generally focus on alcohol con-
sumption alone. The size of the comorbid patient group
is not known. We did not set a specific figure for the
number of patients we needed to identify as database eli-
gible. The key issues were to establish if Read code data
(the standard clinical terminology system used in Gen-
eral Practice in the United Kingdom) were sufficient to
identify cases and if the procedure was acceptable to
practice staff and patients. Acceptability to patients was
judged by their response to the invitation to attend for
screening and informed by feedback from practitioners
and patients in the course of the study.
Efficient recruitment and retention Recent work in
the United Kingdom found that approximately 25% of
screened adult male patients in primary care who scored
more than 7 on AUDIT were willing to be recruited into
an alcohol intervention trial [51] and published recom-
mendations suggest that a retention rate of more than
80% at follow-up would support feasibility [52]. Thus
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recruitment of 25% of screened patients who scored
more than 7 on AUDIT and a retention rate of 80% at
the six-month follow-up were taken as reasonable suc-
cess criteria for a definitive trial.
Analysis
Eligibility, recruitment, and retention rates were calcu-
lated as percentages for the two pilot trials. Descriptive
statistics (mean, standard deviation, and percentages as
appropriate) were used to characterize trial participants
and summarize trial outcomes by arm. Rates of eligibil-
ity, recruitment, and retention between trials were com-
pared using chi-square tests, and AUDIT scores and
characteristics of consenters and non-consenters at base-
line were compared using t-tests.
A sample size calculation for a future trial was carried
out based on estimates of rates of eligibility, recruitment,
retention, and response from this feasibility study, and
publicly available information on average practice size in
England. Since it is unlikely that intraclass correlation
coefficients can be estimated with any degree of preci-
sion from a pilot trial [49] and since there were few clus-
ters in this feasibility study, an estimate was based
instead on other studies in general practice.
Ethical approval
The study received ethical approval from the County
Durham and Tees Valley NHS Research Ethics Commit-
tee (Reference 10/H0908/35, 21 May 2010). Governance
approval for the research was gained from the PCTs act-
ing as trial sites.
Results
Recruiting practices
Of the 82 practices approached, 29 (35.4%) agreed to
participate; 5 of these practices agreed only to the search
of their database, without subsequent trial participation.
Overall, 51.5% of research practices agreed (including
15.2% that agreed only to the database search) compared
with 24.4% of non-research practices (including 2.0%
agreeing only to the database search). The median pa-
tient list size for participating practices was 9,011 (range
3,000 to 29,778) compared with 10,009 (range 810 to
14,847) for non-participating practices. The median pa-
tient list size for practices agreeing only to the database
search was 12,625 (range 5,513 to 29,778). Of the 26
practices across both waves of recruitment that gave a
reason for declining, 30.8% indicated that they were too
busy, and 46.2% stated that the GPs were not interested.
Staff with access rights to identifiable data at each of
the 29 practices were asked to complete the search strat-
egy. Three practices returned partial information only:
one practice manager terminated the searches as she felt
they required too much of the staff member’s time,
another considered that GPs’ extensive use of free text
coding meant that some search results would not be
valid, and another did not respond to requests to complete
the searches. A further practice withdrew from the study
because funds were not available to cover practice costs for
recruitment and did not respond to a query as to whether
they were happy to contribute prevalence data to the study.
Twenty-five practices (86.2% of those agreeing to partici-
pate, 30.5% of all approached) with a median adult patient
list of 7,328 (range 3,490 to 25,903) were able to complete
and provide anonymous searches of their databases. Four-
teen of these practices (56.0%) were research practices.
Prevalence
Prevalence estimates were derived from completed searches
at 25 general practices with adult patient lists totaling
203,691. Of these patients, 67.4% had a record of weekly al-
cohol units consumed, and 13.2% of all adult patients had a
record of exceeding low risk drinking guidelines of 21/14
(m/f) units of alcohol per week, with twice as many men as
women recorded as drinking to excess (Figure 1). Of the
adult patients recorded, 19.1% as hypertensive; 4.0% of
adult patients were both hypertensive and drank exces-
sively. Of the adult patients recorded, 14.3% had a record
of mild or moderate depression or low mood; 2.7% of adult
patients had this record and also drank excessively. A
slightly greater proportion of female patients than male pa-
tients were recorded as having experienced each comorbid
condition (Figure 1). At the five practices which ran a search
limited to the previous year for depression terms, the search
indicated comorbidity for only 1% of adult patients.
Recruitment and retention of patients
Patients were recruited to the study between January
and August 2011 and the final follow-up appointment
took place in February 2012. Figure 2 shows the CON-
SORT diagram of the flow of participants through the
trials. Practices in the hypertension arm were fewer and
larger, with the three GP practices in the hypertension
trial having lists of 7,181, 13,611, and 13,021 adult pa-
tients respectively, while the ten practices in the depres-
sion trial had a median adult patient list of 7,656 (range
4,694 to 10,464).
Hypertension pilot trial
In the hypertension trial, 1,736 patients (73.4% male)
were ‘database eligible’, having a record of excessive
drinking and raised blood pressure. GPs excluded 27 of
these patients (1.5%) and the remaining 1,709 received a
questionnaire by post. Out of those surveyed, 468 returned
a questionnaire (27.4% of the 1,709 surveyed), including
four who did not answer the AUDIT questions. Of these
468 respondents, 166 (35.5% of respondents, 9.6% of those
‘database eligible’) scored positively on AUDIT. Of these
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respondents, 102 were ‘screen eligible’ in that they also
gave consent to be contacted for interview (5.9% of ‘data-
base eligible’, 21.8% of questionnaire respondents, 61.4% of
those scoring positively on the AUDIT). Eighty three indi-
viduals were recruited to the trial (4.8% of ‘database eli-
gible’, 81.4% of ‘screen eligible’). Sixty seven participants
were retained at six months (3.8% of ‘database eligible’,
65.7% of ‘screen eligible’, 80.7% of those recruited), with lit-
tle difference in retention rates between the control arm
(81.2%) and the intervention arm (80.0%).
Of the 19 ‘screen eligible’ patients who were not re-
cruited, seven could not be contacted after an average of
seven attempts, eight withdrew consent when contacted,
two repeatedly failed to attend appointments, and two re-
ported at their appointment that they were currently re-
ceiving treatment for alcohol problems and therefore were
not deemed fully eligible. At six months, four individuals
could not be contacted, three did not attend appoint-
ments, and nine participants withdrew consent (one fol-
lowing an appointment missed by the researcher).
Depression pilot trial
In the depression trial, 1,120 patients (50.3% male) were
‘database eligible’ and GPs excluded 76 of these patients
(6.8%). Two hundred and fifteen patients returned a
questionnaire (20.6% of the 1044 surveyed), including
one who did not answer the AUDIT, 104 (48.4% of re-
spondents, 9.3% of those ‘database eligible’) scored
positively on AUDIT. Seventy of these respondents gave
consent to be contacted for interview and were deemed
‘screen eligible’ (6.3% of ‘database eligible’ 32.6% of ques-
tionnaire respondents, 67.3% of those scoring positive on
the AUDIT). Twenty-nine individuals (2.6% of ‘database
eligible’, 41.4% of ‘screen eligible’) were recruited to the
trial. Nineteen participants (1.7% of ‘database eligible’,
27.1% of ‘screen eligible’, 65.5% of those recruited) were
retained at six months, and the difference between reten-
tion rates of those recruited to the control arm (70.6%)
and the intervention arm (58.3%) was greater than in the
hypertension trial, but not statistically significant.
Of the 41 ‘screen eligible’ patients who were not re-
cruited, 21 were not deemed fully eligible: one scored
higher than 19 and 17 scored lower than 5 on PHQ-9
when measured at the baseline appointment, two pa-
tients indicated they were receiving treatment for alco-
hol problems, and a further patient was found to suffer
cognitive impairment. In addition, eight ‘screen eligible’
patients could not be contacted after an average of seven
Figure 1 Prevalence at 25 practices of hazardous or harmful drinking, hypertension, mild/moderate depression, and comorbidities.
Dotted bars indicate female, lined bars indicate male. DEP, depression, H/H, hazardous/harmful drinking, HYP, hypertension.
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attempts, ten withdrew consent when contacted, and
two repeatedly failed to attend appointments. At six
months, two participants could not be contacted, two re-
peatedly failed to attend appointments and six patients
withdrew consent (one following an appointment missed
by the researcher).
There were significant trends towards higher rates of
questionnaire return and of patient recruitment among
baseline appointment attendees in the hypertension
than in the depression trial (x2 = 16.02, P <0.001 in re-
spect of questionnaire return; x2 = 29.16, P <0.001 in
respect of patient recruitment), and towards a higher
rate of questionnaire respondents screening positive
(AUDIT score >7) in the depression than in the hyper-
tension trial (x2 = 10.26, P <0.01). There were no sig-
nificant trends between the trials in proportions of
respondents who were ‘screen eligible’, baseline appoint-
ments attended, or recruited participants who were retained
at six months.
Characteristics at baseline
AUDIT scores for survey respondents in both trials
(n = 678), and characteristics for those who answered
the demographic questions (n = 381 to n = 678) are re-
ported in Table 1, and were compared to consider any
possible selection bias in the samples [47]. Respondents
Figure 2 CONSORT flow diagram for the Comorbidities and Brief Interventions in Northeast England study (ComBIne). BI, brief
interventions; DNA, did not attend.
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supplying demographic information in the depression trial
were younger and more likely to be employed or female
than those in the hypertension trial. Comparing responses
for those who returned questionnaires in each trial, the
mean AUDIT score was greater among depression trial re-
spondents than among hypertension trial respondents,
with the mean AUDIT score of respondents in the depres-
sion trial indicating hazardous drinking. In the hyperten-
sion trial, there was little difference in age, sex, or
proportion in employment between survey respon-
dents supplying this information in the intervention
and control arms, however, mean AUDIT scores and
the proportion scoring positively on AUDIT were both
higher in the intervention arm (mean AUDIT score
7.9; SD 4.7; 49.1% positive) than in the control arm
(mean AUDIT score 6.5; SD 4.7; 28.6% positive). In the
depression trial, all respondent characteristics at base-
line were similar across intervention and control arms.
AUDIT scores were also compared in each trial be-
tween all those who gave consent to being contacted
and all those who did not, and between AUDIT positive
respondents who gave consent and AUDIT positive re-
spondents who did not. In the hypertension trial, AUDIT
scores were significantly higher for all respondents who
gave consent to contact (n = 249; mean 7.5; SD 5.25) com-
pared to those who did not (n = 215; mean 6.4; SD 4.10)
(1.13 mean difference; 95% CI 0.26 to 2.00; P = 0.011).
Among the 166 respondents scoring positively on AUDIT,
AUDIT scores were not significantly different between
those who gave consent to contact and those who did not.
In the depression trial, AUDIT scores were significantly
higher for all respondents who gave consent (n = 124;
mean 11.9; SD 9.52) compared to those who did not
(n = 87; mean 7.7; SD 5.75) (4.256 mean difference;
95% CI 2.01 to 6.51; P <0.001). Among the 104 re-
spondents scoring positively on AUDIT, AUDIT scores
were significantly higher among those who gave con-
sent to contact (mean 18.1; SD 8.51) than among those
who did not (mean 13.0; SD 5.62) (5.087 mean differ-
ence; 95% CI 1.93 to 8.25; P = 0.002).
Mean AUDIT scores and demographic characteristics
at baseline are reported in Table 2 for those who con-
sented to being contacted by a researcher and were sub-
sequently recruited to either of the two trials at baseline
appointments. Among ‘screen eligible’ respondents who
gave consent to contact in the hypertension trial, those
recruited were older (mean 64 years, SD 9.19) with a
Table 1 Demographic characteristics (age, sex, and
employment rates) and AUDIT scores of survey
respondents in each trial
Hypertension Depression
Mean age in years (SD) 65 (10.6) 54 (14.5)
1nh = 266, nd = 137
% male 83.3 59.7
nh = 275, nd = 139
% not in paid employment 72.8 49.2
nh = 256, nd = 125
Mean AUDIT score (SD) 7.0 (4.8) 10 (8.4)
nh = 464, nd = 214
% AUDIT positive 35.8 49.1
nh = 464, nd=,214
1nh and nd give the total number in each trial supplying relevant data
(hypertension and depression, respectively).
Table 2 Demographic characteristics and outcome
measures at baseline and at six months for patients
recruited to the trial
Hypertension Depression
Control Intervention Control Intervention
Mean age in
years (SD)
63 (8.1) 66 (10.4) 53 (13.3) 50 (16.2)
1nh = 81, nd = 29
% male 89.6 85.7 64.7 75.0
nh = 83, nd = 29
% not in paid
employment
77.3 71.4 50.0 72.7
nh = 77, nd = 27
BASELINE:
Mean AUDIT (SD) 12 (4.7) 12 (4.7) 15 (6.4) 20 (9.7)
nh = 83, nd = 29
Mean PHQ-9 (SD) - - 10 (4.2) 11 (4.7)
nd = 29
Mean Systolic
BP (SD)
153 (19.4) 149 (16.1) - -
nh = 83
Mean Diastolic
BP (SD)
88 (10.1) 87 (8.8) - -
nh = 83
FOLLOW-UP:
Mean AUDIT (SD) 10 (4.7) 9 (3.8) 14 (6.6) 18 (7.3)
nh = 67, nd = 19
% scoring <7 on
AUDIT
25.6 35.7 8.3 0.0
nh = 67, nd = 19
Mean PHQ-9 (SD) - - 9 (5.9) 8 (6.0)
nd = 19
Mean Systolic
BP (SD)
147 (16.4) 149 (16.9) - -
nh = 67
Mean Diastolic
BP (SD)
90 (11.2) 88 (10.7) - -
nh = 67
1 nh and nd give the total number in each trial supplying relevant data
(hypertension and depression, respectively).
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lower mean AUDIT score (mean 12, SD 4.69) than those
who were not recruited (mean 55 years, SD 11.73 and
mean score 13, SD 7.40), and were more likely to be
male (88.0% compared with 75.0%). Among screen eli-
gible respondents giving consent to contact in the de-
pression trial, those recruited were somewhat older (mean
53 years; SD 14.78) with a lower mean AUDIT score
(mean 17; SD 8.29) than those who were not recruited
(mean 48 years, SD 14.71; mean score 21, SD 8.37), and
were more likely to be male (67.4% compared with 59.3%).
None of these differences were statistically significant.
Outcome measures at follow-up
Mean scores for AUDIT, one-off blood pressure read-
ings, and PHQ-9 at six-month follow-up are also re-
ported in Table 2. In the hypertension trial, 35.7% of
followed up on participants in the intervention arm and
25.6% of those in the control arm reported AUDIT
scores at follow-up that were below the cutoff for haz-
ardous drinking (7 or less). Among participants followed
up whose systolic blood pressure had been 140 mmHg
or above at baseline, 21.4% of those in the control arm
and 17.4% of those in the intervention arm had a read-
ing below 140 mmHg at follow-up. Among participants
followed up whose diastolic blood pressure had been
above 85 mmHg at baseline, 12.5% of those in the con-
trol arm and 10.5% of those in the intervention arm had
a reading below 85 mmHg at follow-up.
In the depression trial, 8.3% of participants in the con-
trol arm reported AUDIT scores at follow-up that were
below the cutoff for hazardous drinking (7 or less), how-
ever, none of the seven participants in the intervention
arm scored below this cutoff at follow-up. Of partici-
pants followed up, 33.3% in the control arm and 42.9%
of those in the intervention arm returned a PHQ-9 score
below the cutoff of 5 at follow-up.
Mean changes in outcome measures from baseline are
reported in Table 3 for those participants who were
retained at follow-up. In both arms of the hypertension
trial, mean systolic blood pressure was reduced by an
amount (≥2 mm Hg) cited in the literature as likely to
have a substantive public health impact at a population
level [12,53]. Diastolic blood pressure was increased by a
similar amount at follow-up in both trial arms. In both
arms of the depression trial, mean change in PHQ-9
scores was smaller than the clinically significant change
of 5 points for patients receiving treatment for depres-
sion cited by Löwe et al. [44].
Acceptability of procedures and materials
Field notes of comments from GP practice staff and pa-
tients to the researchers suggested that they generally
found the research procedures acceptable. Four practices
were unable to complete the database searches due to
problems accessing the data, for instance, some practice
managers reported that they were unable to search for
ranges of scores within scales or indicated that data on
alcohol consumption or depression had been entered as
free text and therefore could not be used as a search cri-
terion. No adverse effects were reported.
In the hypertension trial practices patients often com-
pared research appointments to the ‘Well Man’ or ‘Well
Woman’ clinics they attended regularly to discuss blood
pressure, and tended to treat the research appointment
positively as another opportunity to monitor their
health, for instance comparing their blood pressure read-
ing to that at the most recent clinic. Some patients in the
depression trial who were not fully eligible at their base-
line appointment because of a PHQ-9 score below 5 com-
mented that they experienced considerable fluctuation in
depressive symptoms, or suggested that in recently pre-
ceding weeks they might well have returned an eligible
score.
All participants who were scheduled to receive the in-
terventions did so. Patients receiving the brief advice did
not voice any concerns regarding it, though some hyper-
tensive patients commented afterwards that they were
often advised by doctors or nurses to drink less, or were
skeptical of the link between their alcohol intake and
their blood pressure. For instance, one man pointed out
that his last reading at the surgery had been low despite his
having drunk excessively the night before. In comparison,
Table 3 Changes in continuous outcome measures from baseline to six months for participants retained at follow-up.
Hypertension Depression
Intervention (n = 28) Control (n = 39) Intervention (n = 7) Control (n = 12)
Mean change Mean change Mean change Mean change
T2-T1 (SD) T2-T1 (SD) T2-T1 (SD) T2-T1 (SD)
AUDIT score −1.8 (2.92) −1.5 (5.2) −3.1 (4.9) −1.5 (5.0)
Systolic BP −2.0 (17.7) −3.2 (16.8) - -
Diastolic BP 2.2 (10.62) 1.8 (9.12) - -
PHQ-9 score - - −2.9 (5.7) −0.7 (6.1)
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participants receiving the brief advice in the depression
trial appeared more ready to view alcohol intake as related
to their symptoms.
Sample size calculation for a main trial based on the
hypertension trial
The average adult practice list size across the three PCTs
from Wave 1 was 6,366 but across England in 2011 this
was 4928 [54,55]. Based on this latter figure, one would
expect to identify 246 patients per practice as ‘database
eligible’ for a hypertension trial and to recruit and retain
10 patients per practice (to have a cluster size of 10).
The corresponding figures for a depression trial are 74
‘database eligible’ and 2 recruited and retained. As a
guide for a future trial based on the hypertension pilot
study, a sample size calculation was carried out. To have
an 80% power of detecting a standardized difference of
0.3, deemed to be a small difference [56], would require
outcome data on 176 subjects per trial arm. A loss to
follow-up rate of 81% from the feasibility study would
inflate this to 217 recruited per arm. Estimating an intra-
class correlation coefficient of 0.04 from other studies
based in general practice and a cluster size of 10 based
on the feasibility study and average numbers of adults in
GP practices would further inflate the numbers recruited
per arm to 300. The feasibility study found that 5.1% of
patients were ‘database eligible’ for a hypertension trial
and 4.8% of these were recruited into the trial. This im-
plies that 122,563 patients’ records would need to be
screened per arm, implying about 25 practices would be
needed per arm if the average numbers of patients per
practice aged 18 or above were 4,928.
Discussion
This study gathered evidence regarding the feasibility of
a definitive trial of brief intervention to reduce excessive
alcohol consumption in primary care patients with co-
morbidities of hypertension or mild to moderate depres-
sion. Of adult primary care patients identified, 5.1% were
as ‘database eligible’ for the hypertension trial and 1.5%
were ‘database eligible’ for the depression trial. In the
hypertension trial, 4.8% of ‘database eligible’ patients
were recruited into the trial, and 80.7% of these were
retained at six months. In the depression trial, 2.5% of
‘database eligible’ patients were recruited into the trial,
and 65.5% of these were retained at six months. Rates of
eligibility, recruitment, and retention in the hypertension
trial were consistent with results and recommendations
in the literature [50-52], while those in the depression
trial fell somewhat short of these rates. Research tasks
were not perceived as burdensome by patients in either
trial.
In keeping with published recommendations [57], the
study was intended as a pilot from the outset, with
appropriate aims: to assess recruitment potential, test
the research process, and to identify any potential issues
in data management ahead of a full trial [40]. Strengths
of this study include the use of validated instruments to
assess eligibility and measure outcomes and a high rate
of retention at six-month follow-up in one of the trials
(80.7%). The inclusion of 25 practices in the database
searches provides a robust indication of wider preva-
lence rates, though these may reflect regional patterns of
alcohol use and health [58]. However, practices were not
found to screen patients regularly for alcohol consump-
tion and therefore no date limits were applied to the
searches. Information on alcohol consumption may have
been out of date in some cases, leading to both false
positives and false negatives in establishing database eli-
gibility. The implementation of more rigorous screening
in routine primary care would enhance future efforts to
establish prevalence. The observed difference between
mean baseline AUDIT scores for the control and inter-
vention arms in the hypertension trial probably reflects
the small number of large GP practices in this trial, and
suggests that the profiles of patients at those three prac-
tices were not similar. Any such confounding influence
of a small number of large practices in the pilot trial
should be mitigated in a full trial where greater numbers
of practices would be recruited over a wider area. It is
also a limitation that demographic data (such as age and
sex) were not available to assess how respondents and
non-respondents differed, and that demographic ques-
tions were completed by too few AUDIT positive re-
spondents to indicate whether those who gave permission
for contact differed from those who did not. A greater rate
of response to the demographic questions might have
been achieved by providing a more detailed explanation
on the questionnaire and an information leaflet of why
this information was important and how it would be used.
The differing rates of recruitment and retention be-
tween the two linked trials may reflect characteristics of
the sample or target populations. In the hypertension
trial, patients were more likely to be retired with the
time and inclination to visit their GP surgery [59], while
depression trial participants were more likely to be of
working age and bringing up children and therefore hav-
ing less opportunity to attend their GP surgery. Further-
more, men may perceive less of a stigma than women
around admitting to excessive drinking [60], although
they attend GP surgeries less frequently [61]. Since the
hypertension trial participants were mostly male and the
depression trial participants mostly female (consistent
with profiles of patients with those conditions), sex dif-
ferences may have facilitated recruitment to the hyper-
tension trial. As a relatively widespread physical condition,
high blood pressure may have also have less stigma
attached to it than a mental health problem such as
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depression. It is informative that hypertension partici-
pants frequently indicated that they were accustomed
to visiting the surgery to discuss their hypertension,
and tended to treat the research appointment as a
similar demonstration of their conscientiousness or
proactive monitoring of this condition. Finally, the
symptoms of depression may make patients feel less
able to attend the surgery and trials of interventions
via the internet for depression have recently been con-
ducted for this reason [61]. Recruitment in this trial
might have been higher with the offer of research ap-
pointments taking place at patients’ homes.
However, some factors might have been expected to
favor participation in the depression trial rather than the
hypertension trial. Patients with depression might be ex-
pected to be readier to accept and act on advice linking
their drinking with their health condition if they experi-
ence direct impact of alcohol consumption on their
mood. Hypertension patients on the other hand do not
experience an immediate discernible change in symp-
toms after excessive drinking and as such they may be
more ready to accept lay reasoning favoring the per-
ceived benefits of drinking than brief advice on links be-
tween drinking and their comorbid condition [62].
A legitimate aim for a feasibility study is to inform the
selection of outcome measures for a full trial [40,63] and
the results can inform such a choice. Variability in the
single measurements of blood pressure at baseline and
follow-up was relatively high [64], which means there
may be considerable uncertainty using this data when
planning a definitive trial. One-off measurement is now
considered inadequate due to the high variability in
blood pressure readings and confounding influences such
as the white coat effect or recent activity [65,66]. Aggre-
gate measurement over a period of time offers a more ro-
bust indication of blood pressure. Since the study data
were gathered, national guidance has been updated to rec-
ommend 24-hour ambulatory monitoring or an average
reading of home measurements over a week to confirm a
clinical diagnosis of hypertension [67]. At the time of the
study, these more precise methods were not in common
use in primary care. They were liable to constitute an add-
itional intervention if used to measure outcomes because
they require patients to focus their attention on their
blood pressure over a longer period. However, since this
trial was conducted, 24-hour blood pressure measurement
has been added to government recommendations for clin-
ical practice in primary care [67] and is now widely used
by practices, either on its own or combined with home or
clinic monitoring, in management of the blood pressure of
hypertensive patients. As a recommended procedure, this
would not constitute an intervention additional to the
routine management of hypertension, and should there-
fore be acceptable to participants, and it would also
provide more robust and reliable outcome measure-
ment [65,66]. Alternatively, practices are now required
to record the blood pressure of all hypertensive pa-
tients within nine months; these data could potentially
provide a baseline measure without going beyond nor-
mal practice routine.
Depression is less prevalent than hypertension in the
United Kingdom adult population [5,7]. However, the
lower rates of patients eligible from practice lists for the
depression trial may reflect in part previous findings of
inconsistent recording of depression on primary care da-
tabases [68]. The eligibility criterion for depression (PHQ-
9 score 5 to 19 at recruitment) also led to a lower rate of
cases from ‘screen eligible’ respondents in the depression
condition (41.4%) than in the hypertension condition,
where no additional baseline check was made (81.4%).
Greater numbers of eligible patients might have been
identified and recruited in the present study through alter-
native means such as prospective screening a general
population of primary care patients for depression rather
than working from past records of depression or low
mood in practice databases. However, many patients ex-
cluded for a baseline score below 5 described fluctuating
symptoms that a one-off PHQ-9 score might not capture
[69]. This is consonant with findings from a recent
population-based study screening repeatedly for major
depression with PHQ-9 which observed fluctuations in
reported symptoms and the predictive value of PHQ-9
was much lower in an intermediate range of the scale
(score 7 to 14) than in higher and lower ranges [70].
Improvements between assessment and intervention in
both depression and alcohol consumption outcomes
have also been observed in a recent trial of brief inter-
vention with depressed drinkers [71]. Repeated admin-
istration of PHQ-9 has been recommended for clinical
practice [72] and been found to be appreciated by pa-
tients with mental health or substance use conditions
[71,73], and this strategy might be preferable to deter-
mine eligibility and outcome in a trial around comor-
bid mild or moderate depression and excessive drinking.
Patten and Schopflocher 72] recommend serial testing
strategies for use with the general population, particularly
in the immediate range of PHQ-9. Their strategy of six
screenings at two-week intervals might represent a con-
siderable increase in burden for research, however, four
screenings over the same period might be feasible and
provide more useful information than a single screen.
Conclusions
A pilot study is now considered ‘an almost essential pre-
requisite’ to a full-scale study to ensure it will be suc-
cessful [40]. Our findings indicate that a definitive trial
in primary care of BI to reduce excessive alcohol con-
sumption in hypertensive patients is logistically feasible
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and acceptable to practitioners (and, on face value, to
patients) and should be carried out following the design
of this pilot study but adopting a more robust aggregate
outcome measure of blood pressure. Our sample size
calculation suggests that 48 practices would need to be
recruited for this, which would be achievable in a na-
tional trial. In addition, there has been a trend towards
fewer and larger GP practices in England in recent years
[55], suggesting that even fewer practices may ultimately
suffice. Somewhat low rates of compliance among GP
practices were encountered, particularly among non-
research practices, with GPs citing lack of time or inter-
est. It may be important to the successful recruitment of
practices in a future trial to ensure that the study is fully
discussed by all practice members rather than one part-
ner or the practice manager ‘signing up’ the practice to a
study without engaging their whole team.
A future trial would therefore be facilitated by mea-
sures such as ensuring practice participation costs are
covered and that practices are incentivized by funding
structures to participate in research, and engaging with
local service provider networks. A grant funded through
a national peer-reviewed funding stream would provide
additional resource through research networks to engage
more practices, overcoming some of these issues. Since
database searches were not possible on all data manage-
ment systems, it may be advisable for a future trial to
consider limiting recruitment to those practices with
systems and staff that can support such a search. This would
potentially compromise external validity or generalizability,
however, the considerable majority of practices agreeing to
carry out the search strategy for this study were able to
complete it. Although it was anticipated that excessive
drinkers suffering from depression could also benefit from
brief alcohol intervention to reduce their drinking, study
design for such a trial may need further refinement to
identify a broader strategy for screening, as well as an al-
ternative approach to a single administration of PHQ-9
for assessing outcome, such as repeated administration or
an alternative instrument (for example, the widely used
Hospital Anxiety and Depression questionnaire) [74].
Qualitative research to explore patient experience of
screening and assessment for depression would help in-
form this process [71]. Engagement with research appoint-
ments might also be improved in a trial of BI for excessive
drinkers with depression through the use of text re-
minders or home visits. One hour of training, which
would be sufficient for staff to deliver BI, would be most
cost-effective if carried out within existing surgery meet-
ings [75,76]. In respect of both hypertension and depres-
sion trials, identification of patients with these comorbidities
would be facilitated with more widespread and regular alco-
hol screening by practices of their adult patients using vali-
dated tools, and incentivizing practices in this activity
through national remuneration structures would be of bene-
fit to this research.
Definitive trials on this basis will provide robust evi-
dence for preventive approaches to healthcare provision
that can improve the health of substantial patient popu-
lations and ease the burden on health services arising
from their continued excessive drinking.
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